Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials

IMPORTANCE: The subtype of pancreatic ductal adenocarcinoma cancer (PDAC) with DNA damage repair (DDR) deficiency from BRCA1/2 variants has a favorable prognosis and is sensitive to platinum analogues and poly–(adenosine diphosphate–ripose) polymerase (PARP) inhibition with olaparib. Approximately 1...

Full description

Saved in:
Bibliographic Details
Published in:JAMA Oncol
Main Authors: Javle, Milind, Shacham-Shmueli, Einat, Xiao, Lianchun, Varadhachary, Gauri, Halpern, Naama, Fogelman, David, Boursi, Ben, Uruba, Syeda, Margalit, Ofer, Wolff, Robert A., Golan, Talia
Format: Artigo
Language:Inglês
Published: American Medical Association 2021
Subjects:
Original Investigation
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7934074/
https://ncbi.nlm.nih.gov/pubmed/33662100
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2021.0006
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items